Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Reproductive Health

Therapeutic area intelligence for Reproductive Health with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
10
Catalysts
0
Companies
2

Companies

Epic Pharma →
L-Carnitine →

Assets

FDA →
Humanwell →
Impact →
Letrozole →
Linzagolix →

Recent signals(10)

ClinicalAugust 1, 2026

Impact of Neutrophil-to-Lymphocyte Ratio on IVF Outcomes in PCOS Women

The study suggests that systemic inflammation, indicated by the neutrophil-to-lymphocyte ratio, may affect IVF/ICSI outcomes in women with PCOS.

Regulatory
July 31, 2026

FDA Grants Approval for Cetrorelix Acetate Application ANDA218740

The FDA has granted approval for the ANDA218740 application for Cetrorelix Acetate submitted by Humanwell.

RegulatoryJuly 20, 2026

FDA Grants Approval for Carboprost Tromethamine ANDA219529

The FDA has granted approval for the ANDA219529 application for Carboprost Tromethamine submitted by Somerset TherapS LLC.

StrategyJuly 19, 2026

FDA Grants Approval for Clomiphene Citrate ANDA220673 by Ascent Pharms

The FDA has granted approval for ANDA220673, a generic version of Clomiphene Citrate, submitted by Ascent Pharms.

ClinicalJuly 14, 2026

Linzagolix Evaluated for Adenomyosis and Recurrent Implantation Failure in New Study

A prospective case series is evaluating linzagolix for improving live birth rates in patients with adenomyosis and recurrent implantation failure.

ClinicalJuly 11, 2026

Impact of PCOM on Hormonal Response to GnRH in Functional Hypothalamic Amenorrhea

The study investigates the hormonal response to pulsatile GnRH therapy in women with functional hypothalamic amenorrhea, focusing on those with and without polycystic ovarian morphology.

RegulatoryJuly 8, 2026

FDA Grants Approval for Cetrorelix Acetate by Epic Pharma

The FDA has granted approval for the ANDA218740 application for Cetrorelix Acetate submitted by Epic Pharma.

ClinicalJuly 5, 2026

Study on Endometrial Peristalsis Impact on Pregnancy Outcomes in HRT-FET Cycles

A prospective observational study will assess the role of endometrial peristalsis during HRT-prepared frozen embryo transfer cycles.

ClinicalJune 29, 2026

Trial Evaluates Letrozole and L-Carnitine for Sperm Quality in Oligoasthenoteratozoospermia

A randomized trial is assessing the effects of Letrozole and L-Carnitine on sperm quality and ART outcomes in men with idiopathic oligoasthenoteratozoospermia.

RegulatoryJune 23, 2026

FDA Grants AP Status for SUN PHARM's Ganirelix Acetate Supplement

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for SUN PHARM's supplement of Ganirelix Acetate.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.